Liver News and Research

RSS

BioSphere Medical reports fourth-quarter and full-year 2009 results

BioSphere Medical, Inc. – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today reported financial results for the three and 12 months ended December 31, 2009.

10 Feb 2010

$TZD drug may increase fracture risk in older women$

TZD drug may increase fracture risk in older women

A Henry Ford Hospital study finds women with type 2 diabetes who take a commonly prescribed class of medications to treat insulin resistance may be at a higher risk for developing bone fractures.

10 Feb 2010

HealthYes! brings mobile screening services to Colorado

HealthYes!®, a leading preventive medical screening company, is bringing its life-saving mobile screening services to Colorado. Leveraging the most medically advanced, state-of-the-art equipment and techniques in the industry, HealthYes! screens its clients for life-threatening medical conditions and diseases including: heart disease, stroke, abdominal aortic aneurysm, peripheral artery disease, diabetes and liver disease along with osteoporosis.

10 Feb 2010

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Raptor Pharmaceutical Corp., today announced the presentation of cystinosis data at the Annual Lysosomal Disease Network WORLD Symposium 2010, being held February 10-12 in Miami, Florida. Biomarker data from a Phase IIb pilot study of Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") will be the subject of a poster titled, "Correlation of Plasma Cysteamine and WBC Cystine Levels at Steady State in Patients Treated with Cysteamine Bitartrate." The results will also be published in an upcoming issue of the journal Molecular Genetics and Metabolism.

10 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Celsion Corporation announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

New research suggests closantel drug may be useful in combating river blindness

Scientists at The Scripps Research Institute have discovered a potential new use for the drug closantel, currently the standard treatment for sheep and cattle infected with liver fluke. The new research suggests that the drug may be useful in combating river blindness, a tropical disease that is the world's second leading infectious cause of blindness for humans.

10 Feb 2010

Study explores link between HBV genotype C and liver cirrhosis

Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis. However, the relationship between HBV genotypes and liver cirrhosis remains controversial and no study on exploring the association between HBV genotypes and subclinical cirrhosis in community-based population has been reported.

10 Feb 2010

Breast cancer patients taking antidepressant paroxetine at the same time as tamoxifen are at increased risk of death

Women with breast cancer who take the antidepressant paroxetine at the same time as tamoxifen are at an increased risk of death, concludes a study published on bmj.com today.

10 Feb 2010

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Previous studies have shown that assessment of immunoglobulin subclasses in plasma cells by immunohistochemistry (IHC) may be useful in the histopathologic evaluation of autoimmune liver diseases. However, further studies are necessary in order to validate the diagnostic utility of IgM and IgG immunohistochemistry in this specific scenario.

10 Feb 2010

Chi-Fu Trading to market and sell Delcath PHP Systems in Taiwan

Delcath Systems, Inc. (DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System (the Delcath PHP System™). The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore.

9 Feb 2010

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

REGENERX BIOPHARMACEUTICALS, INC. announced today that researchers have correlated Tβ4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin β4 levels were significantly lower in patients with chronic hepatitis B infection and that the magnitude of the reduction of thymosin β4 was closely related to the severity of the hepatic injury and to patient death. Since patients with higher Tβ4 levels survived the disease, changes in Tβ4 values could reflect outcome in some liver failure patients.

9 Feb 2010

Journal highlights toxic nature of herbal medicines

A University of Adelaide forensic pathologist has sounded a worldwide warning of the potential lethal dangers of herbal medicines if taken in large quantities, injected, or combined with prescription drugs.

9 Feb 2010

Combination of blueberries and probiotics protects against intestinal disorders

It is already known that blueberries are rich in antioxidants and vitamins. New research from the Lund University Faculty of Engineering in Sweden shows that blueberry fibre are important and can alleviate and protect against intestinal inflammations, such as ulcerative colitis.

9 Feb 2010

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

MDS Nordion, a global leader in providing products and services for medical imaging and radiotherapeutics, today announced that two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, which includes the use of MDS Nordion's TheraSphere(R) treatment. The two insurance companies and their affiliates together serve more than one-quarter of Americans and do business in all 50 states.

6 Feb 2010

HDC partners with New York surgery center to develop new molecular diagnostic tests for pancreatic cancer

Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to develop new molecular diagnostic tests for the early detection of pancreatic cancer. The Pancreas, Biliary and Liver Surgery Center is under the leadership of Drs. Michael Wayne, Franklin Kassim and Avram Cooperman.

6 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Global cancer rates could be reduced by 40% with prevention strategies, report says

"Forty percent of the 12 million people diagnosed with cancer worldwide each year could avert the killer disease by protecting themselves against infections and changing their lifestyles, experts said on Tuesday," Reuters reports.

4 Feb 2010

Liver News and Research

BioSphere Medical reports fourth-quarter and full-year 2009 results

TZD drug may increase fracture risk in older women

HealthYes! brings mobile screening services to Colorado

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Medicinal chemistry paper related to the discovery of CUDC-101 published

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

New research suggests closantel drug may be useful in combating river blindness

Study explores link between HBV genotype C and liver cirrhosis

Breast cancer patients taking antidepressant paroxetine at the same time as tamoxifen are at increased risk of death

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Chi-Fu Trading to market and sell Delcath PHP Systems in Taiwan

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

Journal highlights toxic nature of herbal medicines

Combination of blueberries and probiotics protects against intestinal disorders

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

HDC partners with New York surgery center to develop new molecular diagnostic tests for pancreatic cancer

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Global cancer rates could be reduced by 40% with prevention strategies, report says

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News